Takeda, BioNumerik drop licensing pact

Takeda and San Antonio-based BioNumerik Pharmaceuticals have terminated their licensing deal for an experimental neuropathy drug. The move to separate came after Tavocept failed two Phase III trials to treat neuropathy in cancer patients earlier this year.

- here's the release on the un-deal